The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
NCT00215800 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 234
Last updated 2013-04-17
Summary
multi-center, double-blind, randomized, placebo-controlled study of the safety and efficacy.
Conditions
- Chronic Fatigue Syndrome
- Myalgic Encephalomyelitis
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
David R Strayer, MD · AIM ImmunoTech Inc.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-12-31
- Primary Completion
- 2004-02-29
- Completion
- 2004-02-29
More Related Trials
-
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
NCT04432298 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
NCT00533091 ·Status: COMPLETED ·Phase: PHASE1
-
Personalized Immunotherapeutic for Antibiotic-resistant Infection
NCT02508584 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
NCT06462144 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
NCT01555580 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Mycophenolate Mofetil in Myasthenia Gravis
NCT00285350 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
NCT01613599 ·Status: COMPLETED
-
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
NCT05514873 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
NCT06958939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Phase 1 Study Accessing the Safety and Tolerability of CBP-307
NCT02280434 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
NCT02115997 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment With TNF Blockade, Infliximab, in Patients With Myositis
NCT00443222 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916 ·Status: RECRUITING ·Phase: PHASE3
-
Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study
NCT04431895 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
NCT06284954 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
NCT05063162 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
NCT02565576 ·Status: COMPLETED ·Phase: PHASE2
-
Detecting Fatigue From Voice in Generalised Myasthenia Gravis
NCT07033559 ·Status: NOT_YET_RECRUITING
-
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
NCT03304054 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT03971422 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies
NCT06524687 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
NCT05728684 ·Status: UNKNOWN ·Phase: NA
-
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
NCT07337785 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Sacral Nerve Stimulation for Mild-to-Moderate or Refractory Rheumatoid Arthritis
NCT04821050 ·Status: UNKNOWN ·Phase: NA
-
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
NCT04163419 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2